欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

全球特发性肺纤维化市场报告(2016-2020年)

Global Idiopathic Pulmonary Fibrosis Market 2016-2020

加工时间:2016-07-26 信息来源:EMIS 索取原文[60 页]
关键词:特发性肺纤维化;间质性组肺疾病;肺部疾病;高分辨率计算机;断层扫描;Nintedanib;吡非尼酮
摘 要:Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.
目 录:

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Pathogenesis

Signs and symptoms

Diagnosis

Management

Epidemiology

PART 06: Pipeline analysis

Lebrikizumab

Tipelukast

Tralokinumab

FG-3019

Simtuzumab

BMS-986020

AF-219

SAR156597

BG00011

PRM-151

PBI-4050

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by ROA

Oral

Parenteral

PART 09: Market segmentation by drug class

Systemic corticosteroids

Immunosuppressants

Tyrosine kinase inhibitors

Anti-fibrotic agents

PART 10: Geographical segmentation

Global idiopathic pulmonary fibrosis market by

geographical segmentation 2015-2020

Idiopathic pulmonary fibrosis market in Americas

Idiopathic pulmonary fibrosis market in EMEA

Idiopathic pulmonary fibrosis market in APAC

PART 11: Market drivers

Special regulatory designations for pipeline candidates

Growth in patient population

Unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges

Unknown disease etiology

Lack of proper diagnosis

Increased use of off-label and alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

Patient assistance programs

Increase in M&A

Rise in public awareness

PART 16: Vendor landscape

Competitive scenario

Market share analysis 2015

Baxter International

Boehringer Ingelheim

F Hoffmann-La Roche

Prometheus Laboratories

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio

© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服